Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COMMENTARY
COMMENTARY
-
BULLETIN
May 24, 2004
-
Brand Equity in the Pharmaceutical Industry
March 8, 2004
-
<Special Contribution> Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)
March 8, 2004
-
March 1, 2004
-
Pursuing the Value of the Japanese Pharm Industry (2)
February 9, 2004
-
<New Series> Pursuing the Value of the Japanese Pharm Industry (1)
January 19, 2004
-
<Special Contribution> Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
-
<Special Contribution> Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets
January 12, 2004
-
November 10, 2003
-
<Special Contribution>
November 3, 2003
-
<Special Contribution>
September 1, 2003
-
Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko President, Pharma Marketing Survey Research Laboratory
August 11, 2003
-
June 9, 2003
-
May 12, 2003
-
March 24, 2003
-
January 20, 2003
-
< Special Contribution >
January 13, 2003
-
BARKER ON DRUGS
December 23, 2002
-
BARKER ON DRUGS (10)
November 18, 2002
-
BARKER ON DRUGS (9)
October 14, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…